MIRA Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIRA research report →
Price Chart
About the company
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog.
- CEO
- Erez Aminov
- IPO
- 2023
- Employees
- 2
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on MIRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.23M
- P/E
- -1.61
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 2.26
- EV/EBITDA
- -1.34
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -112.42%
- ROIC
- -138.81%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-10,493,112
- Net Income
- $-10,442,485-33.0%
- EPS
- $-1.35-164.7%
- OCF Growth
- +16.2%
- FCF Growth
- +16.2%
- 52W High
- $1.69
- 52W Low
- $0.26
- 50D MA
- $0.68
- 200D MA
- $0.91
- Beta
- 1.49
- RSI (14)
- 23
- Avg Volume
- 615.17K
No earnings-call transcripts are available for MIRA yet.
- Free Float
- 63.9%
- Shares Outstanding
- 42.02M
- Float Shares
- 26.86M
of shares held by institutions
27 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 749.59K | ▼ 2.21K |
| Vanguard Group Inc | 660.50K | ▲ 456.85K |
| Geode Capital Management, LLC | 409.12K | ▲ 105.24K |
| Citadel Advisors LLC | 223.63K | ▲ 204.97K |
| Vanguard Fiduciary Trust Co | 220.90K | ▲ 50.23K |
| Blackrock, Inc. | 215.11K | ▼ 29.51K |
| Captrust Financial Advisors | 90.64K | 0 |
| State Street Corp | 76.90K | ▲ 27.80K |
| Northern Trust Corp | 67.73K | 0 |
| Commonwealth Equity Services, LLC | 65.20K | ▲ 12.01K |
| First American Bank | 60.00K | 0 |
| International Assets Investment Management, LLC | 35.00K | 0 |
Held by 22 ETFs
Biggest fund positions in MIRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | Whalen Matthew Pratt | other | 50,000 |
| Jun 12, 26 | Del Giudice Matthew Paul | other | 50,000 |
| Jun 12, 26 | MacPherson Edward Clouston | other | 50,000 |
| Jun 12, 26 | Shekhat Denil Nanji | other | 50,000 |
| Jun 2, 26 | Mushak Andriy | other | 0 |
| Mar 30, 26 | Aminov Erez | other | 83,500 |
| Oct 16, 25 | Aminov Erez | other | 379,000 |
| Oct 16, 25 | Aminov Erez | other | 234,595 |
| Oct 16, 25 | Aminov Erez | sell | 613,595 |
| Mar 26, 25 | Aminov Erez | other | 62,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MIRA coverage
Recent articles, reports, and earnings notes.
No research on MIRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MIRA report →MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
globenewswire.com · Nov 17
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
globenewswire.com · Oct 29
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
globenewswire.com · Oct 22
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
globenewswire.com · Sep 17
Miravalles Gold Corp. Files NI 43-101 Technical Report for Fairfield Gold Project, Nayarit, Mexico
newsfilecorp.com · Sep 3
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
globenewswire.com · Sep 1
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
globenewswire.com · Aug 6
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
globenewswire.com · Jul 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.